Roche’s investigational IL-33-targeting antibody, astegolimab, failed to meet primary endpoints in a pivotal Phase 3 COPD trial, mirroring similar failures by Regeneron and Sanofi's biologics in this indication. The FDA’s regulatory decision will depend on further discussions, complicating Roche’s efforts to expand its portfolio with biologics targeting chronic obstructive pulmonary disease.